3-(1-哌嗪)异喹啉 | 82117-35-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-(1-哌嗪)异喹啉
• 英文名称: 3-(piperazin-1-yl)-isoquinoline
• 英文别名: 3-piperazin-1-ylisoquinoline；quipazine；1-(3-isoquinolinyl)piperazine；3-(piperazin-1-yl)isoquinoline；3-(1-piperazinyl)isoquinoline
• CAS: 82117-35-9
• 化学式: C₁₃H₁₅N₃
• 分子量: 213.282
• InChiKey: PJPJVTSCAFZBGN-UHFFFAOYSA-N

物化性质

• 熔点：
  95-96 °C
• 沸点：
  417.7±25.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[(6,7-dichloro-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazin-4-yl)methyl]-2-fluorobenzoic acid 、 3-(1-哌嗪)异喹啉 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6,7-dichloro-4-(4-fluoro-3-(4-(isoquinolin-3-yl)piperazine-1-carbonyl)benzyl)pyrrolo[1,2-a]pyrazin-1(2H)-one
  参考文献：
  名称：

  Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)

  摘要：

  Herein we describe the discovery of a novel series of pyrrolo[1,2-a]pyrazin-1(2H)-one PARP inhibitors. Optimization led to compounds that display excellent PARP-1 enzyme potency and inhibit the proliferation of BRCA deficient cells in the low double-digit nanomolar range showing excellent selectivity over BRCA proficient cancer cells. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.026
• 作为产物：
  描述：

  4-(异喹啉-3-基)哌嗪-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-(1-哌嗪)异喹啉
  参考文献：
  名称：

  Discovery of imidazole carboxamides as potent and selective CCK1R agonists

  摘要：

  High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was pro. led extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.057

文献信息

• [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1
  申请人：MERCK SHARP & DOHME

  公开号：WO2011149801A1

  公开（公告）日：2011-12-01

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的萘甲酰胺化合物，它们是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions
  作者：Sean W. Reilly、Robert H. Mach

  DOI：10.1021/acs.orglett.6b02591

  日期：2016.10.21

  A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

  据报道，一种简便的钯催化方法为有氧条件下生物相关的芳基哌嗪提供了有效的合成路线。给电子和位阻芳基氯化物被胺化，产率高达 97%，其中使用哌嗪作为溶剂的例子，说明了这些特殊结构的生态友好、经济有效的合成。
• 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related
  申请人：Hoechst-Roussel Pharmaceuticals Incorporated

  公开号：US05229388A1

  公开（公告）日：1993-07-20

  There are disclosed compounds of the formula, ##STR1## where n is 0, 1 or 2; A is ##STR2## where X in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino, cyano, trifluoromethyl or methylthio; Y in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino, cyano, trifluoromethyl or methylthio; m is 1 or 2; k is 1 or 2; R.sub.1 and R.sub.2 are independently hydrogen, loweralkyl, ##STR3## or aryl except that when R.sub.1 is ##STR4## or aryl, R.sub.2 is hydrogen, or alternatively R.sub.1 +R.sub.2 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane, cycloheptane, pyran, thiopyran, indan or piperidine ring; R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl, or alternatively R.sub.3 +R.sub.4 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane, cycloheptane, pyran, thiopyran, pyrrolidine or piperidine ring, the term aryl signifying an unsubstituted phenyl group or a phenyl group substituted with 1, 2 or 3 substituents each of which being independently loweralkyl, loweralkoxy, hydroxy, halogen, loweralkylthio, cyano, amino or trifluoromethyl, which are useful as antipsychotic, analgesic, anticonvulsant and anxiolytic agents.

  公式中披露了化合物，其中n为0、1或2；A为其中X在每次出现时独立地为氢、卤素、较低烷基、羟基、硝基、较低烷氧基、氨基、氰基、三氟甲基或甲硫基；Y在每次出现时独立地为氢、卤素、较低烷基、羟基、硝基、较低烷氧基、氨基、氰基、三氟甲基或甲硫基；m为1或2；k为1或2；R.sub.1和R.sub.2独立地为氢、较低烷基、或芳基，但当R.sub.1为或芳基时，R.sub.2为氢，或者R.sub.1 +R.sub.2与它们附着的碳原子一起形成环戊烷、环己烷、环庚烷、吡喃、硫代吡喃、茚或哌啶环；R.sub.3和R.sub.4独立地为氢或较低烷基，或者R.sub.3 +R.sub.4与它们附着的碳原子一起形成环戊烷、环己烷、环庚烷、吡喃、硫代吡喃、吡咯烷或哌啶环，术语芳基表示未取代的苯基或一个苯基，其上取代基为1、2或3个，每个取代基独立地为较低烷基、较低烷氧基、羟基、卤素、较低烷硫基、氰基、氨基或三氟甲基，这些化合物可用作抗精神病、镇痛、抗癫痫和抗焦虑药物。
• 3-[4-(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinone compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04933453A1

  公开（公告）日：1990-06-12

  3-[4-1-substituted-4-piperazinyl)butyl]-4-thiazolidinone compounds which are useful as antipsychotic, analgesic, anticonvulsant and anxiolytic agents.

  3-[4-（1-取代-4-哌嗪基）丁基]-4-噻唑烷酮化合物可用作抗精神病药、镇痛药、抗抽搐药和抗焦虑药。
• Structure−Activity Relationships of a Series of Novel (Piperazinylbutyl)thiazolidinone Antipsychotic Agents Related to 3-[4-[4-(6-Fluorobenzo[<i>b</i>]thien-3-yl)-1-piperazinyl]butyl]-2,5,5-trimethyl-4- thiazolidinone Maleate
  作者：Nicholas J. Hrib、John G. Jurcak、Deborah E. Bregna、Kendra L. Burgher、Harold B. Hartman、Sharon Kafka、Lisa L. Kerman、Sam Kongsamut、Joachim E. Roehr、Mark R. Szewczak、Ann T. Woods-Kettelberger、Roy Corbett

  DOI：10.1021/jm960268u

  日期：1996.1.1

  butyl thiazolidinones structurally related to this compound were prepared and evaluated in vitro for dopamine D2 and serotonin 5HT2 and 5HT1A receptor affinity. The compounds were examined in vivo in animal models of potential antipsychotic activity and screened in models predictive of extrapyramidal side effect (EPS) liability. The synthesis of these compounds, details of their structure-activity relationships

  HP-236（3- [4- [4-（6-氟苯并[b]噻吩-3-基）-1-哌嗪基]丁基] -2,5,5-三甲基-4-噻唑烷酮马来酸酯； P-9236） （54）显示了潜在的非典型抗精神病药活性的药理学特征。制备了与该化合物结构相关的一系列哌嗪基丁基丁基噻唑烷酮，并在体外评估了多巴胺D2和5-羟色胺5HT2和5HT1A受体的亲和力。在具有潜在抗精神病活性的动物模型中对化合物进行了体内检查，并在预测锥体束外副作用（EPS）责任的模型中进行了筛选。描述了这些化合物的合成，其结构-活性关系的详细信息以及新的先导化合物50的发现，以及化合物50和54的分布图的进一步发展。